Latest Conference Articles

Dermatitis and lymphedema are among the most pertinent adverse effects of radiation to the breast, according to Alexa M. Lantz, MSPAS, PA-C.

Kevin Y. Chen, PharmD, MS, BCOP, CPP, discusses how next-generation sequencing improves biomarker testing and treatment planning in solid tumors.

Adding platinum-based chemotherapy to osimertinib improved overall survival vs osimertinib alone in EGFR-mutated NSCLC, even in high-risk subgroups.

Sevabertinib demonstrated robust, durable responses and manageable safety in both treatment-naive and pretreated patients with HER2-mutant advanced NSCLC.

A patient with breast cancer and generalized anxiety disorder was able to avoid an unnecessary mastectomy with virtual reality, said Kelly Preti, DNP.

A multisite advanced practice optimization model improved patient access through tailored interventions, including redistributing non-APP responsibilities.

Frontline lenvatinib, pembrolizumab, and chemotherapy did not lead to increased overall survival vs chemoimmunotherapy in patients with advanced ESCC.

T-DXd plus pertuzumab improved progression-free survival vs THP regardless of prior therapy, hormone receptor status, or PIK3CA mutations.

The combination of sacituzumab with pembrolizumab did not lead to a decline in physical functioning or quality of life in patients with metastatic TNBC.

Data from a large prospective study identified male and older patients as being more likely to develop CIP and 34% of cases to become chronic.

Adding zabilugene almadenorepvec to SOC chemotherapy and nab-paclitaxel was safe and effective in patients with metastatic pancreatic ductal adenocarcinoma.

Ivonescimab plus chemotherapy improved progression-free survival and response rates with manageable safety vs tislelizumab in advanced squamous NSCLC.

The DESTINY-Breast11 trial found neoadjuvant T-DXd followed by THP improved pathologic complete response vs ddAC-THP in high-risk, HER2-positive early breast cancer.

Long-term NATALEE data show adjuvant ribociclib plus an aromatase inhibitor improves invasive disease–free survival vs AI alone in HR+, HER2– early breast cancer.

Adding perioperative durvalumab to neoadjuvant chemotherapy did not worsen health-related quality of life for patients with muscle-invasive bladder cancer.

A preliminary analysis of a prospective study of patients with solid tumors identified subgroups at risk of depressive symptoms via patient-report outcomes.

Ponsegromab increased body weight in patients with cancer-associated cachexia, yielding greater improvement in those who received ponsegromab previously.

Patient-reported outcomes showed that health-related QOL stayed at baseline for patients with HRRM-positive mHSPC receiving a niraparib regimen.

A 1-time dose of arlo-cel demonstrated safety and efficacy in patients with relapsed or refractory multiple myeloma that was previously treated.

Learn the critical factors in determining prophylaxis for venous thromboembolism, a frequent and serious complication for patients with cancer.

AI-driven decision support can ease oncologists’ workloads and streamline care without reducing autonomy.

CRS and ICANS were observed in 48% and 16%, respectively, of patients with ES-SCLC who received tarlatamab, according to real-world data.

A network to connect patients with unused medications with patients in need brought $18 million of free cancer medication while reducing drug waste.

In the phase 3 SURPASS-ET trial, ropeginterferon alfa-2b outperformed anagrelide as second-line therapy for high-risk essential thrombocythemia.

Heather J. Jackson, PhD, APRN, FNP-BC, NEA-BC, FAA-NP, shared a review of supportive oncology practices at the 2025 School of Nursing Oncology.

The addition of atezolizumab to chemoradiation led to meaningful improvements to quality of life for patients with small cell lung cancer.

Heather Jackson, PhD, APRN, FNP-BC, NEA-BC, FAA-NP, explains the utility of a holistic approach to oncology care.

An LED-based intraoral device for photobiomodulation therapy was safe and reduced severe oral mucositis in patients with head and neck cancers.